| Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study DW Eyre, SF Lumley, D O'Donnell, M Campbell, E Sims, E Lawson, ... elife 9, e60675, 2020 | 287 | 2020 |
| The dosing and monitoring of vancomycin: what is the best way forward? PG Drennan, EJ Begg, SJ Gardiner, CMJ Kirkpatrick, ST Chambers International journal of antimicrobial agents 53 (4), 401-407, 2019 | 82 | 2019 |
| Bayesian therapeutic drug monitoring software: past, present and future P Drennan, M Doogue, SJ van Hal, P Chin International Journal of Pharmacokinetics 3 (4), 109-114, 2018 | 28 | 2018 |
| Predictive performance of Bayesian vancomycin monitoring in the critically ill SW Narayan, Y Thoma, PG Drennan, HY Kim, JW Alffenaar, S Van Hal, ... Critical care medicine 49 (10), e952-e960, 2021 | 19 | 2021 |
| In healthy volunteers, taking flucloxacillin with food does not compromise effective plasma concentrations in most circumstances SJ Gardiner, PG Drennan, R Begg, M Zhang, JK Green, HL Isenman, ... PLoS One 13 (7), e0199370, 2018 | 19 | 2018 |
| Mycobacterium tuberculosis transmission in Birmingham, UK, 2009–19: An observational study TM Walker, M Choisy, M Dedicoat, PG Drennan, D Wyllie, F Yang-Turner, ... The Lancet Regional Health–Europe 17, 2022 | 15 | 2022 |
| Total flucloxacillin plasma concentrations poorly reflect unbound concentrations in hospitalized patients with Staphylococcus aureus bacteraemia PKL Chin, PG Drennan, SJ Gardiner, M Zhang, SC Dalton, ST Chambers, ... British journal of clinical pharmacology 84 (10), 2311-2316, 2018 | 15 | 2018 |
| Bayesian forecasting for intravenous tobramycin dosing in adults with cystic fibrosis using one versus two serum concentrations in a dosing interval PG Drennan, Y Thoma, L Barry, J Matthey, S Sivam, SJ van Hal Therapeutic Drug Monitoring 43 (4), 505-511, 2021 | 14 | 2021 |
| Assessment of an institutional guideline for vancomycin dosing and identification of predictive factors associated with dose and drug trough levels Q Gu, N Jones, P Drennan, TEA Peto, AS Walker, DW Eyre Journal of Infection 85 (4), 382-389, 2022 | 7 | 2022 |
| Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid PG Drennan, JK Green, SJ Gardiner, SCL Metcalf, CMJ Kirkpatrick, ... British journal of clinical pharmacology 87 (12), 4681-4690, 2021 | 7 | 2021 |
| In vivo human keyhole limpet hemocyanin challenge in early phase drug development: A systematic review PG Drennan, D Karponis, D Richards, M Coles, JN Fullerton Clinical and Translational Science 16 (3), 357-382, 2023 | 5 | 2023 |
| Clinical decision support in a hospital electronic prescribing system informed by local data: experience at a tertiary New Zealand centre PKL Chin, QY Chuah, AM Crawford, OR Clendon, PG Drennan, ... Internal medicine journal 50 (10), 1225-1231, 2020 | 4 | 2020 |
| Determinants of vancomycin nephrotoxicity when administered to outpatients as a continuous 24-hour infusion ST Chambers, M Long, SJ Gardiner, PKL Chin, M Yi, SC Dalton, ... International journal of antimicrobial agents 55 (6), 105972, 2020 | 2 | 2020 |
| Evidenced Based Drug-Drug Interaction Alerts in an E-Prescribing System M Doogue, A Crawford, H Miller, P Drennan, Q Chuah, M Strowther, ... Clinical Therapeutics 39 (8), e18, 2017 | 1 | 2017 |
| Systemic antibiotic prophylaxis in arthroplasty–a narrative review of how many doses are optimal P Wahl, P Drennan, M Schläppi, Y Achermann, M Leunig, E Gautier, ... EFORT Open Reviews 9 (12), 1106-1119, 2024 | | 2024 |
| Immunogenicity of MVA-BN vaccine deployed as mpox prophylaxis: a prospective cohort study and analysis of transcriptomic predictors of response PG Drennan, N Provine, SA Harris, A Otter, J Hollett, C Cooper, ... | | 2024 |
| In vivo human keyhole limpet haemocyanin challenge in early phase drug development: A systematic review P Drennan, D Karponis, D Richards, M Coles, J Fullerton BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 89 (3), 1252-1252, 2023 | | 2023 |
| Assessment of a vancomycin dosing guideline and identification of predictive factors associated with dose and drug trough levels Q Gu, N Jones, P Drennan, TEA Peto, AS Walker, DW Eyre medRxiv, 2022.03. 21.22272606, 2022 | | 2022 |
| Pharmacokinetic-pharmacodynamic target attainment and clinical outcomes in patients treated with oral flucloxacillin plus probenecid P Drennan, J Green, S Gardiner, S Metcalf, C Kirkpatrick, R Everts, ... | | 2020 |
| P152 Practical challenges to daily intravenous tobramycin dosing in patients with cystic fibrosis L Barry, P Drennan, S Sivam, S Van Hal Journal of Cystic Fibrosis 19, S99, 2020 | | 2020 |
